BioCentury
ARTICLE | Distillery Therapeutics

Infectious disease

October 11, 2018 7:27 PM UTC

Mouse studies suggest TLR3 inhibitors could help treat herpes simplex virus type 1 (HSV-1)-induced encephalitis. In a mouse model of HSV-1 encephalitis, an anti-TLR3 antibody decreased CNS viral levels and increased survival compared with control IgG. Next steps could include testing other TLR3 inhibitors in models of HSV-1 encephalitis.

Johnson & Johnson has CNTO 3157 (CNTO3157, JNJ-42915925, PRV-300), an anti-TLR3 mAb, in Phase II testing for asthma and Phase I testing for inflammation, and in Phase I testing for inflammatory bowel disease (IBD) with partners with MorphoSys AG and Provention Bio Inc...

BCIQ Company Profiles

University of Tokyo

BCIQ Target Profiles

Toll-like receptor 3 (TLR3)